19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Shanghai Junshi licenses anti-PD-1 mAb to CSPC

Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize an undisclosed anti-PD-1 mAb in combination with...
19:56 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed PFS data for Pomalyst triple combo in Phase III for MM

Celgene Corp. (NASDAQ:CELG) reported additional data from the Phase III OPTIMISMM trial in 559 patients with relapsed or refractory multiple myeloma (MM) who received prior treatment with Revlimid lenalidomide showing that Pomalyst pomalidomide plus Velcade...
17:44 , Jul 11, 2018 |  BC Extra  |  Company News

Shanghai Junshi licenses anti-PD-1 mAb to CSPC

Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize an undisclosed anti-PD-1 mAb in combination with...
22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
17:57 , May 4, 2018 |  BioCentury  |  Politics, Policy & Law

A Remembrance: An exceptional responder

Jane Reese-Coulbourne was an exceptional responder. In 1990, faced with a diagnosis of advanced breast cancer, she enrolled in a clinical trial at the National Cancer Institute, enduring a grueling regimen of high doses of...
15:34 , May 4, 2018 |  BC Week In Review  |  Clinical News

Karyopharm planning selinexor submissions in MM

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported that selinexor (KPT-330) met the primary endpoint of improving overall response rate (ORR) in the Phase IIb STORM trial to treat penta-refractory multiple myeloma. Based on the data, the company...
23:12 , Apr 30, 2018 |  BC Extra  |  Clinical News

Karyopharm planning selinexor submissions in MM

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) gained $3.06 (24%) to $16.14 in after-hours trading Monday after reporting that selinexor (KPT-330) met the primary endpoint of improving overall response rate (ORR) in the Phase IIb STORM trial to...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
23:23 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample and mouse studies suggest inhibiting IL-18 or NLRP1 could help treat MM. In patient samples, high bone marrow plasma levels of IL-18 correlated with poor overall survival. In two mouse...
22:06 , Feb 23, 2018 |  BC Extra  |  Company News

Darzalex guidance buoys Genmab shares

Genmab A/S (CSE:GEN; Pink:GMXAY) gained DKK13.6 billion ($2.3 billion) in market cap across two days of trading after issuing an earnings report that included new 2018 guidance for multiple myeloma (MM) drug Darzalex daratumumab. Based...